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Introduction
When the first generation of antibiotics appeared in the 1940s,
geneticists suggested that, taking into account the low frequency
of appearance of spontaneous mutants found in nature, the
emergence of resistance during therapy was unlikely. However,
the fact that bacteria are easily able to store and exchange genetic
information, coupled with the high pressure resulting from the
indiscriminate use of antibiotics, has determined the existence
and rapid spread of different resistance mechanisms. Such
mechanisms limit possible therapies and lead to clinical
complications that may end in death. For those reasons, bacterial
resistance to antibiotics has become a major threat to the human
population. In Spain, the development of antibiotic resistance
in community-acquired bacterial pathogens and its relation to
antibiotic use and consumption have been of both national and
international concern [7]. Risk analysis has been suggested as a
suitable practice in order to find guidelines for minimizing the
development of antibiotic resistance [8]. The progressive
emergence and rapid dissemination of resistance to glycopeptide
antibiotics is one of the most dramatic example of such types
of resistance [52]. The glycopeptide antibiotics vancomycin and
teicoplanin (Fig. 1) are considered to be the last resort for treating
a variety of serious infections caused by Gram-positive bacteria,
such as enterococci, methicillin-resistant Staphylococcus aureus
(i.e. MRSA) and Clostridium difficile. Although enterococci are
part of the normal microbiota of the gastrointestinal tract in humans
and other animals, under certain circumstances they are able to
produce nosocomial infections [34]. In fact, enterococci are now
the second most common pathogens isolated from hospital-
acquired infections. Vancomycin has been used heavily in the
last two decades, resulting in the emergence of enterococci resistant
to glycopeptide antibiotics. Vancomycin-resistant enterococci
(VRE) are being increasingly isolated from clinical specimens,
and infections caused by VRE are sometimes untreatable by
currently available antibiotics.
Resistance to vancomycin was first reported in England
in 1988. In the USA, it rose from 0.3% of the hospital isolates
sent to the Center for Disease Control and Prevention
(Atlanta, GA) in 1989 to 15.4% in 1997. Also in the USA,
the percentage of resistant isolates from intensive care units
rose from 0.4 to 23.4 % [21, 45]. In contrast to the USA, the
prevalence rates of VRE in European hospitals are low. A
multicenter study of resistance in enterococci showed that
the rate of resistance to glycopeptides in Spain was 1.8% for
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Glycopeptide resistance 
in enterococci
Summary The selective pressure resulting from the extensive use of antibiotics over
the last 50 years has led to the emergence of bacterial resistance and to the dissemination
of resistance genes among pathogenic microorganisms. Consequently, we are now
at serious risk of suffering intractable, life-threatening infections. The progressive
emergence and rapid dissemination of resistance to glycopeptides, the last resort for
treating nosocomial infections with enterococci resistant to usual antibiotics, constitute
one of the most dramatic examples of such resistance. Enterococci are normal human
commensals, but are also a frequent cause of nosocomial urinary tract infections and
nosocomial bacteremia. Enterococcus faecalis causes 80 to 90% of human enterococcal
infections, while Enterococcus faecium accounts for most of the remainder. During
the last decade, our understanding of the genetics and biochemical basis of resistance
to glycopeptides has increased greatly. Furthermore, the application of molecular
methods for the diagnosis of glycopeptide-resistant enterococci has provided new
insights into the epidemiology of enterococcal infections.
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vancomycin and 1% for teicoplanin [12]. However, Spain
has been recognized by the scientific community as one of
the countries with the highest rates of bacterial resistance to
antibiotics, which indicates that controlling the emergence
of new types of resistance is required [7]. Furthermore, the
apparently low prevalence of VRE in Spanish hospitals as
well as in hospitals in other European countries may be due
to the inability of the diagnostic laboratories to detect all
VRE [2].
The most worrying features of resistance to vancomycin
are: (1) the lack of synergy when vancomycin is combined with
aminoglycosides, (2) the high frequency of simultaneous
resistance to several antibiotics and (3) the putative risk of
spread to more virulent bacteria, such as Staphylococcus aureus
and Streptococcus pneumoniae. The rapid emergence and spread
of VRE has become a serious concern to both physicians and
patients. The emergence of resistance among enterococci
threatens to make vancomycin obsolete in the treatment of
infections caused by these bacteria [5, 54]. Resistance is
observed most commonly in Enterococcus faecium, which is
often resistant to aminoglycosides and β-lactams, and to a lesser
extent in other Enterococcus spp., including E. faecalis [34].
Several authors have reviewed glycopeptide resistance in
enterococci [5, 21, 54, 55]. Over the last five years, our
understanding of the molecular basis of resistance has increased
considerably, new types of acquired glycopeptide resistance
have appeared, and several VRE outbreaks have occurred. In
this review, we provide an update on different aspects of
glycopeptide resistance, and briefly describe new molecular
techniques for the rapid, accurate diagnosis of VRE.
The cell wall of Gram-positive eubacteria
The strength of the cell wall of eubacteria depends mainly on
the peptidoglycan component. The chemical composition of
that peptidoglycan is very similar in Gram-negative and in Gram-
positive bacteria. The peptidoglycan layer comprises two sugar
derivatives, N-acetylglucosamine and N-acetylmuramic acid,
and a group of amino acids, usually consisting of L-alanine,
D-glutamic acid, D-alanine, and either diaminopimelic acid
(DAP) or another amino acid, which is L-lysine in the case of
most Gram-positive cocci.
The peptidoglycan is a multilayered structure in which
the glycan chains formed by sugars are connected by peptide
cross-links formed by amino acids (Fig. 2). This cross-linking
is essential for the full strength of the peptidoglycan structure,
and occurs to varying degrees which are characteristic in
different bacteria. There are almost 100 known peptidoglycan
types, and the greatest variation occurs in the interbridge. Any
of the amino acids present in the tetrapeptide can also occur
in the interbridge; besides, other amino acids can be found.
In Gram-positive eubacteria, cross-linkage is usually
established by a peptide interbridge, the kinds and numbers
of cross-linking amino acids varying from organism to
organism.
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Fig. 1 Structure of vancomycin and teicoplanin
In S. aureus, the best-studied Gram-positive eubacteria,
each interbridge peptide consists of five glycine molecules
connected by peptide bonds (Fig. 3A). Alternatively, the
interbridge of many staphylococci strains consists of glycine
associated with alanine and/or serine. In E. faecalis the cross-
bridge between D-Ala and L-Lys consists of one or two alanine
molecules (Fig. 3B) [16]. In other enterococci, such as 
E. faecium, the cross bridge contains D-aspartate (D-Asp) or 
D-asparagine (D-Asn) as the sole amino acid [9, 15]. Changes
in the interbridge or in the tetrapeptide lead to several types of
antibiotic resistance found in different bacteria. However,
acquired resistance to glycopeptides in enterococci is due to
production of peptidoglycan precursors ending in the
depsipeptide D-alanyl-D-lactate (D-Ala-D-Lac) instead of the
dipeptide D-alanyl-D-alanine (D-Ala-D-Ala) found in susceptible
bacteria. Variations in the composition of the dipeptide explain
the existence of different types of resistance to glycopeptides—
e.g. E. gallinarum synthesizes peptidoglycan precursors ending
in D-alanyl-D-serine (D-Ala-D-Ser) (Fig. 3C) [44].
De Jonge et al. [16] have studied the muropeptide
compositions of isogenic vancomycin-susceptible and -resistant
E. faecalis strains. The peptidoglycan of the susceptible strain
contains pentapeptides as stem peptides, whereas the
peptidoglycan of the isogenic resistant strain is composed of
muropeptides with tetrapeptide stem peptides. The resistant strain
synthesizes peptidoglycan precursors terminating in D-Ala-D-Lac
rather than D-Ala-D-Ala; however, no lactate-containing
muropeptides are detected in its peptidoglycan [9, 16]. 
73Glycopeptide resistance INTERNATL MICROBIOL Vol. 3, 2000
Fig. 2 Overall structure of the enterococcal peptidoglycan. The diagram depicts
several glycan chains cross-linked to one another. G: N-acetylglucosamine;
M: N-acetylmuramic acid. Thick lines represent interbridges
Fig. 3 (A) Glycine interbridge in Staphylococcus aureus. (B) Interbridge in glycopeptide resistant enterococci. (C) Variations in the composition of the
peptidoglycan precursor
De Jonge et al. suggested that either lactate-terminating precursors
are not incorporated into peptidoglycan of the resistant strain or
that the lactate residues are removed from peptidoglycan during
synthesis. The degree of cross-linkage observed in both
vancomycin-resistant and -susceptible E. faecalis strains was the
same, indicating that transpeptidation was not affected.
Glycopeptide antibiotics: Mechanism 
of action
Although more than 200 glycopeptides have been identified, only
vancomycin and teicoplanin have been developed for clinical
application thus far [54]. A third glycopeptide, avoparcin, has
been used extensively in agricultural applications and in veterinary
medicine in Europe [21]. The potential agricultural applications
of a fourth agent, actaplanin, have been studied, but this
glycopeptide has not yet been marketed. A fifth agent, ristocetin,
appeared promising in early clinical trials, but development was
stopped because of its toxicity. The glycopeptides are complex
structures that consist of a multiring peptide core (the aglycone
component) containing six peptide linkages, an unusual triphenyl
ether moiety, and sugar molecules that are attached at various sites
(Fig. 1). In vancomycin, the aglycone component is made up of
seven amino acids, joined together to give a heptapeptide. The
side chains of several of the amino acids are crosslinked, resulting
in a closely-packed structure. Two sugars are attached to the side
chain of amino acids [36]. As with the other glycopeptides,
vancomycin is produced by several Actinomyces species isolated
from soil samples, but recently, Nicolau et al. [36] achieved total
synthesis in the laboratory. The latest achievement by Nicolau’s
group is the conversion of vancomycin aglycone to vancomycin
by adding two sugars. This is a significant piece of work because
it demonstrates that selective addition of modified sugars to the
vancomycin aglycone is possible in principle. It has been
established that the sugars of glycopeptides are important in
promoting their activity, and so vancomycin with modified sugars
would have enhanced activity against both VRE and MRSA [36]. 
The molecular target of glycopeptide antibiotics is the 
D-Ala-D-Ala terminus of the N-acetyl-muramyl-pentapeptide
subunit of the growing cell wall in Gram-positive bacteria. By
binding to this terminal dipeptide, glycopeptide antibiotics interfere
with proper cell wall formation, which results in cell death [54].
Teicoplanin, a lipid-containing glycopeptide, has the same
mechanism of action as vancomycin, but its action might be
enhanced by its ability to be anchored in the membrane.
Many Gram-positive pathogens including streptococci,
staphylococci, clostridia and corynebacteria are susceptible in
vitro to vancomycin and teicoplanin. However, some Gram-
positive bacteria (Enterococcus casseliflavus, E. flavescens,
E. gallinarum and many lactobacilli) are intrinsically resistant
to glycopeptide antibiotics [5]. Gram-negative bacteria are, in
general, resistant to glycopeptides because these antibiotics are
unable to cross the outer cell envelope.
Resistance mechanisms: phenotypes and
genes involved in resistance
In vancomycin susceptible enterococci, the dipeptide D-Ala-
D-Ala synthesized by D-Ala:D-Ala ligases (Ddl) is added to a
tripeptide precursor to form a pentapeptide precursor [54]. The
D-Ala-D-Ala terminus is the target of vancomycin, which only
binds after the transfer of cytoplasmic muramyl-pentapeptide
to the lipid and further transfer across the membrane. Once
vancomycin binds to the target, the utilization of the
pentapeptide precursor for cell-wall synthesis is blocked.
However, enterococci have developed a sophisticated
mechanism to overcome glycopeptide antibiotics. Glycopeptide-
resistant enterococci evade the action of vancomycin by
modifying the antibiotic’s molecular target: D-Ala-D-Ala, to 
D-Ala-D-Lac or D-Ala-D-Ser [10, 20]. Vancomycin binds these
peptidoglycan precursors with greatly reduced affinity [10].
At least five glycopeptide resistance phenotypes (VanA, VanB,
VanC, VanD and VanE) can be distinguished in enterococci on
the basis of the level and inducibility of resistance to
vancomycin and teicoplanin (Table 1). VanA and VanB are the
most common resistance phenotypes.
VanA-type glycopeptide resistance is characterized by
acquired resistance to high levels of both vancomycin and
teicoplanin; resistance is induced by either vancomycin or
teicoplanin. VanA-type resistance has been described for
Enterococcus faecalis, E. faecium, E. durans, E. raffinosus, 
E. hirae, E. avium and E. gallinarum [13, 32, 40, 47, 48, 54].
VanB-type resistance is characterized by acquired resistance
to various concentrations of vancomycin but not to teicoplanin;
resistance is induced only by vancomycin and not by
teicoplanin. VanB-type glycopeptide resistance has been
described for E. faecalis, E. faecium, E. gallinarum and
E. raffinosus [13, 28, 32]. The genes encoding the VanA and
VanB phenotypes are carried on transposons Tn1546 and
Tn1547, respectively, which may be found on plasmids or
inserted on the chromosome [5]. The vanA and vanB operons
contain seven genes (Fig. 4). The functions of the proteins
encoded by six of these genes have been studied extensively
[see review in ref. 5]. Genes vanS (vanSB) and vanR (vanRB)
encode a two-component signal-transducing regulatory system
required for the induction of resistance genes in response to
the presence of glycopeptide antibiotics in the medium. VanA-
and VanB-type strains are therefore characterized by the
inducible expression of resistance genes. The vanA or vanB
and vanH (vanHB) genes enable enterococci to synthesize
peptidoglycan precursors terminating in D-Ala-D-Lac, rather
than in D-Ala-D-Ala [1, 25, 31]. vanA and vanB encode ligases
which ligate D-Lac to D-Ala, and vanH (vanHB) encodes a
dehydrogenase which synthesizes D-Lac from pyruvate. The
vanX (vanXB) and vanY (vanYB) genes encode a DD-dipeptidase
and a DD-carboxypeptidase, respectively, which eliminate the
production of peptidoglycan precursors ending in D-Ala-D-Ala
[43, 44]. The DD-dipeptidase cleaves the D-Ala-D-Ala dipeptide
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from the pentapeptide precursor, and the DD-carboxypeptidase,
a Zn2+-dependent enzyme, removes the C-terminal D-Ala 
[4, 5]. The vanA operon contains another open reading frame,
vanZ, which encodes a protein that confers low-level teicoplanin
resistance by an unknown mechanism. On the other hand, the
vanB operon contains vanW, but the function of the
corresponding protein is unknown [22].
The VanC phenotype is characterized by constitutive low-
level resistance to vancomycin and susceptibility to
teicoplanin, and is an intrinsic property of most E. gallinarum, 
E. casseliflavus and E. flavescens isolates [20, 54]. This type
of resistance requires three proteins: VanC and VanXYC, which
catalyze the synthesis of D-Ala-D-Ser and which eliminate
precursors ending in D-Ala-D-Ala, and VanT, a membrane-
bound racemase for production of D-Ser [42, 20, 35, 3]. The
nucleotide sequences of the vanC-1 (E. gallinarum), vanC-2
(E. casseliflavus), and vanC-3 (E. flavescens) have been
published [20, 35]. There is extensive homology between the
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Table 1 Types of glycopeptide resistance in Enterococcus spp.
Type(1) Expression Location of MIC (µg/ml) Transferable by Termination of Species
genes conjugation peptidoglycan
Vancomycin Teicoplanin precursor
VanA Inducible Chromosome and  >128 >64 + D-Ala-D-Lac E. faecium
plasmids (Tn1546) E. faecalis (2)
VanB Inducible Chromosome and 16–1024 <2 + D-Ala-D-Lac E. faecium
plasmids (Tn1547) E. faecalis (2)
VanC Constitutive Chromosome 4–16 0.5–1 – D-Ala-D-Ser E. gallinarum
E. casseliflavus
E. flavescens(3)
VanD Inducible or Chromosome 64–128 4 – D-Ala-D-Lac E. faecium
constitutive(4) E. faecalis
VanE Inducible ND(5) 16 0.5 – D-Ala-D-Ser E. faecalis
(1)All glycopeptide-resistance types are acquired, except VanC which is an intrinsic property of E. gallinarum,
E. casseliflavus and E. flavescens. For references see text.
(2)VanA and VanB resistance types have also been found in other Enterococcus spp. (see text for details).
(3)E. casseliflavus and E. flavescens are now considered the same species [27].
(4)Constitutive in E. faecalis BM4339 [41]; inducible in E. faecium A803, A804, and A902 [38].
(5)ND, not determined.
Fig. 4 Schematic representation of the vanA (A), vanB (B), and vanD (C) operons. PR and PH are the promotors controlling the gene expression
vanC-2 and vanC-3 genes. In fact, in a recent study, 
E. casseliflavus and E. flavescens were found to be a single
species, and the term “E. casseliflavus” was recommended
to be retained as the species denomination [27]. The vanC
gene products are structurally related to D-Ala:D-Ala ligases
and to D-Ala:D-Lac ligases [23]. Apart from vanC, these strains
also contain the chromosomal ddl gene that encodes the 
D-Ala:D-Ala ligase [35]. Unlike the genes determining the
VanA- and VanB-type resistances, the vanC genes are located
exclusively on the bacterial chromosome. The vanC-1 gene
product synthesizes D-Ala-D-Ser that replaces the D-Ala-D-Ala
terminus in peptidoglycan precursors [39, 44]. Insertional
inactivation of vanC-1 in E. gallinarum caused reversion to
vancomycin susceptibility, indicating that vanC-1 is necessary
for expression of vancomycin resistance [20]. The
peptidoglycan precursors of the insertional mutant 
end in D-Ala-D-Ala. The gene downstream from vanC-1
encodes VanXYc, which has both DD-dipeptidase and 
DD-carboxypeptidase activities [42]. The VanXYc protein is
similar to VanY in an overlap of 158 amino acids, and contains
consensus sequences for binding zinc, stabilizing the substrate
and catalyzing hydrolysis, present in both VanX (VanXB) and
VanY (VanYB). Unlike VanX, VanXYc has very low
dipeptidase activity against D-Ala-D-Ser, and unlike VanY, it
has no activity against peptidoglycan precursors ending in 
D-Ala-D-Ser [42]. The function of VanXYc seems to be the
hydrolysis of D-Ala-D-Ala and the removal of C-terminal 
D-Ala from peptidoglycan precursors ending in D-Ala-D-Ala.
E. gallinarum also produces VanT, a membrane-bound serine
racemase which catalyses conversion of L- to D-Ser [3].
Insertional inactivation of the vanC-1 gene has a polar effect
on the expression of vanXYC and vanT genes.
E. gallinarum isolates that carry both the vanA and vanC-1
genes have been described [40]. Besides, the vanC-1 gene has
been detected in some strains that, under phenotypic analysis,
appeared to be E. faecalis and E. faecium [40; Pérez-Hernández
X, Méndez-Álvarez S, Claverie-Martín F, unpublished data]. 
Recently, two new types of acquired glycopeptide
resistance, designated as VanD and VanE, have been described
in E. faecium and E. faecalis strains, respectively [24, 41].
These two types of resistance are uncommon because only
a few isolates have been identified. The VanD phenotype is
characterized by resistance to intermediate levels of
vancomycin and to low levels of teicoplanin (Table 1),
and is a result of synthesis of D-Ala-D-Lac-terminating
peptidoglycan precursors [41]. The VanD phenotype has been
found in E. faecium BM4339 and in three other E. faecium
isolates [38, 41].
In E. faecium BM4339, the VanD phenotype is expressed
constitutively [41], whereas in three other isolates the
vancomycin resistance is induced by vancomycin [38]. The
genes determining the VanD phenotype appear to be located
on the chromosome and are not transferable to other enterococci
[38, 41]. This could explain the scarcity of recognized VanD
strains in contrast to the widespread and high-prevalence VanA
and VanB strains.
The vanD gene cluster contains six genes: vanRD, vanSD,
vanRYD, vanHD, vanD and vanXD (Fig. 4C) [11]. The deduced
VanHD dehydrogenase, VanD ligase, and VanXD DD-dipeptidase
are highly similar to the corresponding proteins encoded by
the vanA and vanB operons. The deduced VanYD protein is
homologous to penicillin-binding proteins that display DD-
carboxypeptidase activity. No genes homologous to vanZ and
vanW from the vanA and vanB operons, respectively, have been
found in the vanD gene cluster [11]. The D-Ala:D-Ala ligase
of E. faecium BM4339 is not functional due to a frameshift
mutation in the chromosomal ddl gene. However, the growth
of BM4339 does not depend on the presence of glycopeptides,
because the expression of the vanD genes in this strain is
constitutive [41]. 
VanE-type resistance has been described in one only strain
of E. faecalis, BM4405, which is resistant to low levels of
vancomycin and susceptible to teicoplanin [24]. Resistance in
BM4405 is inducible by vancomycin. A gene with homology
to vanC has been partially characterized. This is consistent with
the fact that strain BM4405 synthesizes peptidoglycan
precursors that end in D-Ala-D-Ser. A serine racemase activity
is present in the membrane fraction of BM4405. Therefore,
VanE-type resistance is due to synthesis of peptidoglycan
precursors ending in D-Ala-D-Ser. It is unknown whether the
resistance genes are located on the chromosome or in plasmids. 
Regulation of glycopeptide resistance
The presence of vancomycin or teicoplanin induces the
expression of the vanA operon in VanA-type resistant
enterococci. Induction takes place at the transcriptional level
by a two-component regulatory system, VanR-VanS [reviewed
in ref. 54]. The presence of the glycopeptide in the medium
results in autophosphorylation of a histidine residue on the
VanS sensor. The phosphoryl group is transferred to an aspartate
residue on the response regulator VanR. The phosphorylated
VanR binds to the vanRP and vanHP promoter regions, and
activates transcription of the vancomycin resistance genes 
(Fig. 4A). As with other response regulators, phosphorylation
of VanR increases its affinity for the promoter region, which
is essential for activation of transcription [26, 53]. 
The regulatory mechanism in VanB strains must be different
because, in contrast to the vanA operon, the VanRB-VanSB
system mediates promoter activation only in the presence of
vancomycin. VanB-type constitutive variants harbor mutations
in the vanSB sensor gene. These mutations are thought to impair
dephosphorylation of the VanRB regulator [6].
The VanRD and VanSD proteins from E. faecium BM4339
contain the characteristic amino acids involved in protein
phosphorylation, as well as the motifs conserved in response
regulators and protein kinases [11]. Casadewall and Courvalin
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[11] have suggested that the constitutive phenotype of 
E. faecium BM4339 may be a result of mutations located near
the putative autophosphorylation site, and which are known to
alter the phosphatase activity of VanSB [6]. Alternatively, the
signal recognition properties of VanSD may be impaired,
resulting in phosphorylation of VanRD, even in the absence
of vancomycin.
Origin of glycopeptide resistance 
in enterococci
The origin of the genes encoding high-level resistance to
glycopeptides in enterococci is unknown. It has been postulated
that, under the pressure of increased glycopeptide usage both
in agriculture and in clinical practice, the vancomycin resistance
genes present in other microorganisms of the environment may
have been transferred to enterococci [45]. Both the intrinsically
vancomycin-resistant lactic acid bacteria (Leuconostoc,
Pediococcus, and Lactobacillus) and the glycopeptide-producing
microorganisms are potential reservoirs. Alternatively, the genes
may have originated through mutations in homologous genes
within enterococci or other bacteria. Leuconostoc mesenteroides
produces a D-Ala:D-Lac ligase and a D-lactate dehydrogenase,
although its ligase differs notably from that of enterococci in
a region that is critical for catalysis. Marshall et al. [29] have
cloned three genes encoding homologues of VanH, VanA
(VanB) and VanX from both Streptomyces toyocaensis and
Amycolatopsis orientalis, two organisms which produce
glycopeptide antibiotics. Furthermore, the arrangement of the
vanH, vanA (vanB), and vanX genes in these organisms is
identical to the arrangement found in VRE. These results
indicate that glycopeptide-producing organisms use a resistance
mechanism that is similar to that found in VRE, and suggest
that they have been the source of resistance genes in VRE.
However, not all the vancomycin resistance genes may have
been acquired in a single transfer from another organism. There
is very strong evidence that the basic mechanism evolved in
one of the producer organisms, but the regulatory system could
easily have come from another Gram-positive bacterium.
Accordingly, the G+C contents of the VRE vanH, vanA (vanB),
and vanX genes are 5–10% higher than those of the adjacent
vanR, vanS, vanY, and vanZ (or vanW) [29]. It seems therefore,
that glycopeptide-producing organisms with different G+C
contents than S. toyocaensis and A. orientalis genes may have
served as donors of the vanHA(B)X gene cluster. Alternatively,
bacteria that do not produce glycopeptide may have acquired
the glycopeptide resistance genes as a defense mechanism, and
eventually they may have passed them to enterococci.
It has been hypothesized also that a gene resembling the
vancomycin resistance genes in enterococci might have
conferred vancomycin resistance to Bacillus popiliae [46].
Since biopesticides containing spores of B. popiliae have been
used for more than fifty years in the United States for
agricultural purposes, this bacterium might have served as donor
of the vancomycin resistance gene.
Epidemiology
Enterococci have emerged in recent years as pathogens in a
growing number of severe nosocomial infections. Especially
worrying is the increased number of VRE. Knowledge of the
epidemiology of VRE is essential to prevent it from spreading.
Note that the epidemiology of enterococci resistance to
vancomycin shows different patterns in Europe and in USA.
In Europe, resistance to vancomycin has been detected not only
in hospital samples, but also in community-acquired infections,
as well as in asymptomatic carriers and farm animals. The
emergence of such resistant strains has been associated with
the use of avoparcin, a glycopeptide antibiotic that has been
used as a growth promoter in farm animals [47]. The use of
avoparcin may have provided a selective pressure for the
emergence of VRE in poultry and pigs, which probably are a
major reservoir of VRE for humans [50]. Some human isolates
are indistinguishable from isolates derived from animal sources,
which suggests that VRE from animals may pass to humans
via the food chain. For this reason, avoparcin administration
has been restricted in the European Union. In contrast, in USA,
where avoparcin has never been licensed, vancomycin resistance
has only been detected in hospitals. Emergence of such
resistance is associated with frequent vancomycin admin-
istration, especially via the oral route, and with the use of high
doses of the antibiotic [17].
The spread of VRE involves the clonal dissemination of a
single resistant strain and the genetic transfer of resistance-
encoding plasmids and/or transposons between different strains
or even between different species. Since phenotypic detection
of low vancomycin resistance levels by the usual sensitivity tests
is difficult, molecular techniques such as Polymerase Chain
Reaction (PCR), genetic fingerprinting, Pulsed Field Gel
Electrophoresis-Restriction Fragment Length Polymorphisms
(PFGE-RFLPs), etc. permit an improvement not only in diagnosis
but also in the knowledge of the numbers and types of resistant
strains at a given time in a given location. This knowledge is
useful for the design of plans for prevention, care and control of
the emergence of vancomycin resistance, and for the
establishment of rules for the proper use of antibiotics.
Molecular methods to study
glycopeptide resistant enterococci
Since some vancomycin resistance genes are transferable among
different enterococcal species or even among different genera
[54], the lack of prompt detection of enterococci may cause
delays in attempting to eliminate VRE colonization and
infection. Conventional identification methods, which are based
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on culturing bacteria, require two to three days to provide
results, and even then are not discriminatory enough. The
development of rapid, sensitive PCR-based assays has improved
the speed and accuracy of the diagnosis of enterococcal
infections. PCR provides a means for culture-independent
detection of enterococci in a variety of clinical specimens, and
can yield results in just a few hours. Several PCR-based methods
for the specific detection of enterococci have been reported
[14, 19, 27]. One such method is based on targetting the ddl
gene, permitting the specific detection of E. faecalis and E.
faecium [19]. For the specific detection of E. gallinarum and
E. casseliflavus/E. flavescens, a PCR assay amplifying different
vanC genes has been developed [14, 19]. Recently, Ke et al.
[27] have developed a rapid PCR assay for the specific detection
of all enterococci of clinical importance at the genus level. By
targeting the tuf gene, which encodes elongation factor EF-Tu,
this method makes it possible to detect most enterococcal
species to a highly sensitive degree, with acceptable specificity
[27].
PCR can be used to discriminate between different kinds
of genes encoding resistance to glycopeptides. In this instance,
primers that specifically hybridize to different conserved DNA
sequences in the different resistant genotypes are used to
amplify particular gene fragments that allow different resistance
types to be distinguished [19, 40, 51]. Recently, a Multiplex
PCR assay that allows simultaneous detection of glycopeptide
resistance genes (vanA, vanB, vanC-1) and identification at the
species level, of clinically relevant enterococci (E. faecium,
E. faecalis, E. gallinarum, E. casseliflavus) has been developed
[19]. Another method developed by Patel et al [40] is a 
PCR-RFLP assay which can be performed directly with isolated
colonies of Enterococcus spp. to detect and discriminate vanA,
vanB, vanC-1 and vanC-2/3 genes. The recent cloning and
characterization of the vanD and vanE genes will permit the
development of PCR assays for the specific detection of these
new types of glycopeptide resistance [24, 41]. Subsequent DNA
sequencing of the PCR fragments gives information on the
variability of glycopeptide resistance genes within each type
of resistance class.
Other molecular tests allow to obtain an accurate, precise
identification of each isolate, as well as to estimate the genetic
diversity within each resistance type. The determination of 16S
ribosomal RNA sequences has become a common procedure
[27, 33]. Fragments of the 16S rRNA can be retrieved from the
bacteria by applying PCR with a set of primers known as 16S
rRNA primers. The 16S rDNA fragment can be sequenced, and
the sequence compared to all the isolates and to those in a large
database. The sequence information is sufficient to classify a
strain to a genus or species level. Alternatively, ribotyping or
ARDRA (Amplified Ribosomal DNA Restriction Assay) can
be performed. To carry out the ribotyping, a 16S rDNA fragment
is labeled and hybridized against digested genomic DNA in
order to obtain a hybridization pattern which, depending on
the experimental conditions, may show specificity at subspecies,
species or genus levels [49]. ARDRA involves the digestion
of the PCR fragment with restriction enzymes that cut in the
variable or hypervariable regions of the 16S rRNA gene.
Additionally, other methods are available to perform rapid
analyses that provide a tool for determining subtle differences
among highly-related enterococci. Such molecular tools include
REP-PCR (Repetitive Extragenic Palindrome PCR), RAPD
(Random Amplified Polymorphic DNA) and RFLP [18, 33, 51].
REP-PCR is based on the fact that genomes of microorganisms
contain repetitive sequences. In the genomes of different
enterococci, the repetitive sequences are in different relative
locations to each other. Distances between pairs of repetitive
elements that are not more than a few kilobase-pairs apart can
be determined by PCR, and the result is a number of DNA
fragments differing in size. In this way, subtle genome
differences between strains can be detected relatively quickly,
although the method does not work when a particular strain
contains too few or unknown repetitive elements. RAPD has
been shown to be very efficient in distinguishing related
enterococcal isolates [33]. This method is based on the
amplification of genomic DNA sequences by using a single
random primer that is not targeted towards any specific DNA
sequence in the genome. Under low-stringency conditions, a
number of different sites of annealing are present on the genome
depending on the length, on the nucleotide sequence and on the
G+C content of the primer. This technique performed on a given
genomic DNA generates a pattern of amplification products.
RFLP analyses also attempt to generate banding patterns that
reflect genetic differences between bacteria. RFLP analyses
can be performed in several different variations: patterns generated
by ARDRA (see this section above) and PFGE macrorestriction
have been the most successful to date. PFGE macrorestriction
patterns involve the comparison of total DNAs cleaved with a
restriction enzyme that cuts infrequently, and separated by PFGE
[30, 51]. PFGE has been demonstrated to be a suitable typing
method for enterococci [51]. Furthermore, the capacity of PFGE
to separate long DNA fragments, even chromosomal or 
high-molecular-weight extrachromosomal elements, combined
with hybridization techniques, allows elucidation of the type of
genetic element harboring a specific DNA sequence. 
Finally, it should be taken into account that, in some studies,
only the combination of different molecular techniques will
yield the desired degree of discrimination. 
Concluding remarks
The mechanism by which resistant enterococci evade the action
of glycopeptides is based on the use of altered peptidoglycan
precursors that have low affinity for the antibiotic. Genetic
variations have led to the existence of at least five different
glycopeptide resistance types, some of which are encoded in
transferable genetic elements, i. e. transposons or plasmids
(Table 1). Two of these five types, VanD and VanE, have been
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described only recently, and we should be ready to face the
emergence of new resistance types. Furthermore, the
transferable nature of inducible resistance operons is a putative
risk of the spread of glycopeptide resistance to more virulent
bacteria. Although the transfer of vancomycin resistance genes
has not been reported in a clinical setting, the transfer of vanA
genes from E. faecalis to S. aureus has been demonstrated in
vitro [37].
Since phenotypic typing methods are not discriminatory
enough, to stop the spread of VRE, it is essential to use
molecular techniques that allow a rapid, accurate identification
of enterococci and their resistance type. Thus, fast, accurate
molecular methods will be an essential diagnostic tool for
microbiology laboratories.
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